Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose Cyclophosphamide by 媛뺣�몄씪 et al.
© 2013 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Two Cases of Refractory Thrombocytopenia in Systemic Lupus 
Erythematosus that Responded to Intravenous Low-Dose 
Cyclophosphamide 
Treatment of thrombocytopenia in systemic lupus erythematosus (SLE) is considered in 
cases of current bleeding, severe bruising, or a platelet count below 50,000/µL. 
Corticosteroid is the first choice of medication for inducing remission, and 
immunosuppressive agents can be added when thrombocytopenia is refractory to 
corticosteroid or recurs despite it. We presented two SLE patients with thrombocytopenia 
who successfully induced remission after intravenous administration of low-dose 
cyclophosphamide (CYC) (500 mg fixed dose, biweekly for 3 months), followed by 
azathioprine (AZA) or mycophenolate mofetil (MMF). Both patients developed severe 
thrombocytopenia in SLE that did not respond to pulsed methylprednisolone therapy, and 
started the intravenous low-dose CYC therapy. In case 1, the platelet count increased to 
50,000/μL after the first CYC infusion, and remission was maintained with low dose 
prednisolone and AZA. The case 2 achieved remission after three cycles of CYC, and the 
remission continued with low dose prednisolone and MMF. 
Key Words: Cyclophosphamide; Systemic Lupus Erythematosus; Thrombocytopenia
Hee-Jin Park, Mi-il Kang, Yoon Kang, 
Soo-jin Chung, Sang-Won Lee,  
Yong-Beom Park, and Soo-Kon Lee
Division of Rheumatology, Department of Internal 
Medicine, Yonsei University College of Medicine, 
Seoul, Korea
Received: 20 July 2012
Accepted: 7 December 2012
Address for Correspondence:
Sang-Won Lee, MD
Division of Rheumatology, Department of Internal Medicine, 
Yonsei University College of Medicine, 250 Yonsei-ro, 
Seodaemun-gu, Seoul 120-752, Korea
Tel: +82.2-2228-1947, Fax: +82.2-393-6884
E-mail: sangwonlee@yuhs.ac
http://dx.doi.org/10.3346/jkms.2013.28.3.472 • J Korean Med Sci 2013; 28: 472-475
CASE REPORT
Immunology, Allergic Disorders & Rheumatology
INTRODUCTION
Systemic lupus erythematosus (SLE) is the prototypic inflam-
matory autoimmune disease characterized by multi-organ in-
volvement. Hematological manifestations in the revised criteria 
for the classification of SLE include hemolytic anemia, leuco-
penia, lymphopenia, and thrombocytopenia (1).
 Treatment of thrombocytopenia in SLE is considered in cas-
es of current bleeding, severe bruising, or a platelet count below 
50,000/μL (1). For SLE patients suffering from complex and life-
threatening thrombocytopenia, high dose corticosteroid should 
be administered first. When thrombocytopenia does not re-
spond to corticosteroid monotherapy, or when it recurs despite 
corticosteroid therapy, other medications such as danazol, in-
travenous immunoglobulin, and immunosuppressants can be 
added to the corticosteroid (1-4).
 Intravenous cyclophosphamide (IV CYC) is widely used in the 
treatment of proliferative lupus nephritis (class III and IV). Re-
cently, low-dose IV CYC (500 mg/day, biweekly for 3 months) fol-
lowed by azathioprine (AZA) or mycophenolate mofetil (MMF) 
has been reported to exhibit effects similar to those of a high-
dose IV CYC regimen (National Institutes of Health protocol: 
750-1,000 mg/m2 body surface area, monthly), but with fewer 
complications such as infection or bone marrow suppression 
than high-dose IV CYC regimen (5). Previous reports have also 
revealed that a high-dose CYC regimen was effective for refrac-
tory thrombocytopenia in SLE (2, 3). However, there are few re-
ports on the efficacy of a low-dose IV CYC regimen in SLE pa-
tients with refractory thrombocytopenia.
 Here, we report two SLE patients with refractory thrombocy-
topenia who successfully recovered after the administration of 
low-dose IV CYC followed by AZA or MMF.
CASE DESCRIPTION
Case 1
A 24-yr-old woman had been diagnosed with SLE according to 
the presence of antinuclear antibody (ANA) and anti-ds DNA, 
pancytopenia, and arthritis in June 2010. At the time of diagno-
sis, she had an ANA titer of 1:640, mixed type; an anti-ds DNA 
level of 571.3 AU (ELISA, positive, ≥ 92.6 AU); a white blood cell 
(WBC) count of 560/µL (neutrophils, 82.6%; lymphocytes, 2.6%); 
a platelet count of 65,000/µL; and a hemoglobin concentration 
of 6.7 g/dL. The erythrocyte sedimentation rate (ESR) was 2 mm/ 
h, and the C-reactive protein (CRP) concentration was 4.80 mg/
L. Complements 3 and 4 were decreased to 22.1 mg/dL (normal: 
90-180 mg/dL) and 5.65 mg/dL (normal: 10-40 mg/dL), respec-
tively. We performed a bone marrow biopsy that showed no ab-
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normal findings. Concluding that the leucopenia and thrombo-
cytopenia were hematological manifestations associated with 
SLE, we started administration of prednisolone (1 mg/kg/day) 
and AZA (25 mg/day). The thrombocytopenia improved, with 
an increased platelet count above 100,000/µL, and the dose of 
prednisolone was tapered to 15 mg/day. However, she was ad-
mitted with fever, pleuritic chest pain, and pancytopenia, in-
cluding severe thrombocytopenia, 6 months later. Laboratory 
results on admission showed that WBC and platelet counts were 
2,250/μL (neutrophils, 86.3%; lymphocytes, 7.6%) and 10,000/
μL, respectively. The hemoglobin concentration was 6.7 g/dL, 
and the corrected reticulocyte percentage was 1.04%. The ESR 
was 39 mm/hr, and the CRP concentration was 33.02 mg/L. Com-
plements 3 and 4 were reduced to 36.4 and 9.1 mg/dL, respec-
tively, while the anti-ds DNA level had increased, from 497.3 to 
548.3 AU (ELISA). Computed tomography of the chest and ab-
domen revealed pericardial and bilateral pleural effusion, but 
not splenomegaly. To rule out other diseases, including hemo-
phagocytic syndrome and aplastic anemia, we performed a bone 
marrow biopsy. The results showed normal cellularity and abun-
dant megakaryocytes, suggesting severe thrombocytopenia in 
SLE. She received pulsed intravenous methylprednisolone (1,000 
mg/day) for 3 days, followed by oral prednisolone (1 mg/kg/day) 
and intravenous immunoglobulin (5 g/day) for 5 days. The ane-
mia, leucopenia, and serositis were markedly improved, but the 
platelet count was still 11,000/μL after finishing pulsed methyl-
prednisolone therapy. Next day after pulsed methylpredniso-
lone therapy, she began low-dose IV CYC therapy (500 mg/day, 
biweekly). Her platelet count increased to 50,000/μL on day 11 
after the first CYC infusion, and a stable platelet count above 
100,000/μL was maintained with no CYC complications. She 
completed six cycles of low-dose IV CYC therapy over 3 months 
and could decrease the dose of prednisolone. She maintained on 
low-dose prednisolone (10 mg/day) and 50 mg of AZA, and her 
platelet count was remained above 150,000/µL after 12 months 
(Fig. 1A).
Case 2
A 47-yr-old woman was admitted for 2-month recurrent oral 
ulcer, anemia, and skin lesions, including purpura and petechiae, 
on August 14, 2010. On admission, laboratory results showed 
WBC and platelet counts of 3,700/μL (neutrophils, 55.6%; lym-
phocytes, 34.5%) and 5,000/μL, respectively. The hemoglobin 
concentration was 7.4 g/dL; the corrected reticulocyte percent-
age was 1.15%; the ESR was 33 mm/hr; and the CRP concentra-
tion was < 0.1 mg/L. Levels of ferritin and LDH were not ele-
vated, to 4.2 ng/mL (normal: 11-306 ng/mL) and 223 IU/L (nor-
mal: 119-247 IU/L), respectively. Neither proteinuria nor hema-
turia was observed. ANA was detected at a titer of 1:640, but anti-
ds DNA was negative. Complements 3 and 4 were 78.7 and 11.5 
mg/dL, respectively. She was diagnosed with SLE according to 
the presence of ANA and lupus anticoagulant, the recurrent 
oral ulcer, and thrombocytopenia. Abdominal ultrasonography 
showed no splenomegaly. And a bone marrow biopsy showed 
50%-60% cellularity and abundant megakaryocytes, suggesting 
peripheral thrombocytopenia. She received intravenous dexa-
methasone (20 mg/day) and immunoglobulin (5 g/day) for 5 
days, and then was maintained on a moderate dose of prednis-
olone (30 mg/day). However, 1 month later, her platelet count 
had decreased to 9,000/μL. She received pulsed intravenous 
methylprednisolone (1,000 mg/day) for 3 days and immuno-
globulin (5 g/day) for 5 days, followed by oral prednisolone (1 
mg/kg/day). However, this combination treatment showed no 
efficacy. She started low-dose IV CYC (500 mg/day, biweekly) 
on September 16 and achieved induction of remission after 
three cycles of CYC. After she finished six cycles of low-dose IV 
Fig. 1. Changes of platelet count in patients with multiple medical treatments. (A) In case 1, the pateint recurred severe thrombocytopenia and recieved methylpredinoslone 
pulse therapy for 3 days and intravenous immunoglobulin (IVIG) for 5 days. She did not respond these medications and started low- dose intravenous cyclophosphamide (IV CYC) 
therapy. She achieved remission of thrombocytopenia after the first IV CYC therapy, and a stable platelet count was maintained. (B) In case 2, the platelet count of patient was 
decreased below 10,000/µL and received methylpredinoslone pulse therapy and IVIG. However, this combination treatment showed no efficacy. The platelet count was increased 
above 50,000/µL after three cycles of IV CYC, and it remained at stable level. Doses of steroids are presented according to the potency of prednisolone. MP pulse therapy, in-
travenous methylprednisolone pulse therapy (1,000 mg/day for 3 days); IVIG, intravenous immunoglobulin; IV CYC, intravenous infusion of low-dose cyclophosphamide.
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CYC therapy in the outpatient clinic, started AZA (50 mg/day) 
with reducing the dose of prednisolone to 15 mg/day. However, 
she switched from AZA to MMF (500 mg/day) because her plate-
let count was decreased to 41,000/µL when she was maintained 
on AZA. After maintenance on MMF, she showed a stable plate-
let count without relapse into thrombocytopenia or complica-
tions due to the medication after 24 months (Fig. 1B).
DISCUSSION
Thrombocytopenia occurs in 7%-30% of SLE patients; about 
25%-50% of these cases show mild thrombocytopenia (plate-
lets, 100,000-150,000/µL), and about 10% are severe thrombo-
cytopenia (platelets, < 50,000/µL) (2, 3). Thrombocytopenia is 
often mild in SLE and usually requires no specific drug therapy 
(6). When thrombocytopenia is moderate to severe, corticoste-
roids such as prednisolone (1 mg/kg/day) or pulsed methyl-
prednisolone therapy (1,000 mg/day for 3 days) are the initial 
management choice for inducing remission (1). When the dis-
ease does not respond, or when intolerably high doses of corti-
costeroids are required, intravenous immunoglobulin, danazol, 
and immunosuppressive agents can be complementary treat-
ments. If medical treatment of thrombocytopenia with pred-
nisolone or other medications is unsuccessful, a splenectomy 
should be considered. However, the role of splenectomy in the 
management of severe thrombocytopenia in SLE remains con-
troversial (9-11). Thus, medical therapies such as immunosup-
pressants and IVIG are recommended as the first choice for lu-
pus thrombocytopenia refractory to corticosteroids. Among 
immunosuppressants, AZA is traditionally considered a steroid-
sparing agent for the treatment of thrombocytopenia in SLE. 
Cyclosporine A, MMF, and CYC can be used as alternative im-
munosuppressants for refractory thrombocytopenia (3, 7, 8). 
Especially in the treatment of severe cytopenias and aplastic 
anemia in SLE, more cytotoxic treatments such as CYC are often 
needed (1).
 CYC was initially used for lupus nephritis class III and IV, and 
was not commonly used for isolated thrombocytopenia in SLE. 
In previous studies, Reiner et al. (4) showed that IV CYC therapy 
was effective in 20 patients with refractory autoimmune throm-
bocytopenic purpura. Boumpas et al. (2) investigated the effects 
of monthly high-dose IV CYC therapy (750-1,000 mg/m2 body 
surface area, similar to the National Institutes of Health proto-
col for lupus nephritis) in patients with autoimmune thrombo-
cytopenia. They demonstrated that all patients arrived at nor-
mal platelet counts within one to four cycles of IV CYC therapy.
 The Euro-Lupus Nephritis Trial recently showed that a remis-
sion-inducing regimen of low-dose IV CYC (500 mg fixed dose, 
biweekly for 3 months) followed by AZA or MMF achieved clin-
ical results comparable to those with high-dose IV CYC therapy 
in lupus nephritis, and had fewer side effects (5, 12). Random-
ized studies showed that both MMF and AZA were effective as 
maintenance therapies (13). Thus, low-dose IV CYC followed 
AZA or MMF therapy is commonly used to induce remission of 
nephritis in SLE. However, few reports on the resolution of re-
fractory thrombocytopenia in SLE after low-dose IV CYC thera-
py have been published to date (7).
 We investigated the efficacy of low-dose IV CYC therapy (500 
mg/day, biweekly for 3 months) in two patients with severe 
thrombocytopenia (platelets, < 20,000/μL) in SLE and who 
failed to respond to high dose steroid and pulsed methylpred-
nisolone therapy. Both patients recovered from thrombocyto-
penia, with counts above 100,000/μL, without a splenectomy 
and did not experience any side effects of CYC. In case 1, the 
patient received AZA as a maintenance therapy, and 7 months 
later, the dose of prednisolone was reduced to 10 mg/day. In 
case 2, the patient was maintained on MMF because AZA was 
not effective in maintaining the platelet counts, and the dose of 
prednisolone was reduced to 10 mg/day 6 months later. Subse-
quently in both patients, the platelet count remained stable for 
longer than 1 yr.
 In conclusion, we experienced two patients with SLE who 
achieved remission of thrombocytopenia with low-dose IV CYC, 
with no complication or splenectomy. Here, we suggest that 
low-dose IV CYC followed by AZA or MMF therapy can be an 
effective treatment for inducing remission of severe thrombo-
cytopenia refractory to corticosteroids in SLE.
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